A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors

Inclusion Criteria: 1. Voluntarily signed an informed consent form and were able to complete the study procedures and follow-up examinations and treatment 2. Age ≥ 18 years and ≤ 70 years, regardless of gender 3. Weight \> 40 kg 4. Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 1 5. Patients with refractory advanced solid tumors who have failed or are intolerant of existing standard regimens or whose patients have refused standard regimens 6. The presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors 1.1 criteria 7. With good organ function 8. Positive HER2 cell membrane expression 9. Women of childbearing potential must have a pregnancy test with negative results within 7 days prior to initiation of treatment Exclusion Criteria: 1. Any systemic antitumor therapy within 2 weeks prior to the single blood collection 2. History of organ transplantation 3. Pregnant or lactating women 4. Uncontrolled infectious disease, such as baseline Hepatitis B Virus DNA ≥ 1000 IU/ml, anti-HIV positive, Hepatitis C Virus-RNA positive 5. Other clinically significant active infections 6. Other active malignancies within the previous 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or in situ breast cancer that has been completely cured and does not require follow-up treatment subjects are not included 7. Patients with severe autoimmune or immunodeficiency diseases, such as subjects with a confirmed diagnosis of a severe autoimmune disease requiring systemic immunosuppressive (steroid) therapy for a prolonged period of time (more than 2 months) or with immune-mediated symptomatic diseases, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (e.g., Wegener's granulomatosis), etc 8. Subjects with known severe allergic reactions to pretreatment drugs such as injectable cyclophosphamide, injectable paclitaxel (albumin-bound), or CAR-T cell preparations including adjuvants, dimethylsulfoxide 9. Any unstable systemic disease: including but not limited to unstable angina pectoris, cerebrovascular accident or transient ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association (NYHA) classification ≥ Class III congestive heart failure, severe arrhythmias poorly controlled by medications, liver, kidney or metabolic disease, and hypertension uncontrolled by standard therapy 10 10. Those with active bleeding, thrombotic disorders requiring treatment 11. Patients with pericardial, thoracic, or abdominal effusions requiring clinical management or intervention 12. The presence of known or suspected brain metastases, including central nervous system and spinal cord compressions or meningeal metastases 13. Subjects undergoing treatment with systemic steroids or steroid inhalers 14. Subjects with any psychiatric disorder, including dementia, altered mental status, that may interfere with informed consent and understanding of relevant questionnaires 15. Having participated in another clinical trial within the previous 30 days 16. Have received a live or attenuated vaccine within 4 weeks prior to pretreatment 17. Those who have been judged by the investigator to have a serious uncontrollable disease or have other conditions that may interfere with receiving treatment in this study and are considered unsuitable